Invasive carcinoma of breast
Item
documented invasive breast cancer
boolean
C0853879 (UMLS CUI [1])
Neoplastic Cell Percentage Estrogen receptor positive | Neoplastic Cell Percentage Progesterone receptor positive
Item
greater than 10% tumor cells positive for estrogen receptor and/or progesterone receptor
boolean
C0597032 (UMLS CUI [1,1])
C0439165 (UMLS CUI [1,2])
C0279754 (UMLS CUI [1,3])
C0597032 (UMLS CUI [2,1])
C0439165 (UMLS CUI [2,2])
C0279759 (UMLS CUI [2,3])
Disease HER2 Positive | Disease HER2 Negative
Item
her2+ and her2- (human epidermal growth factor receptor) disease
boolean
C0012634 (UMLS CUI [1,1])
C2348909 (UMLS CUI [1,2])
C0012634 (UMLS CUI [2,1])
C2348908 (UMLS CUI [2,2])
Rapid disease progression | Tamoxifen | anastrozole | exemestane
Item
rapid disease progression despite treatment with tamoxifen, anastrozole or exemestane
boolean
C1834700 (UMLS CUI [1])
C0039286 (UMLS CUI [2])
C0290883 (UMLS CUI [3])
C0851344 (UMLS CUI [4])
ECOG performance status
Item
ecog performance status = 0 or 1
boolean
C1520224 (UMLS CUI [1])
Prior Hormone Therapy Neoplasm Metastasis
Item
prior hormonal therapy for metastatic disease
boolean
C1514460 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
Prior Hormone Therapy Letrozole | Other Coding
Item
prior hormonal therapy with letrozole for adjuvant disease
boolean
C1514460 (UMLS CUI [1,1])
C0246421 (UMLS CUI [1,2])
C3846158 (UMLS CUI [2])
Metastatic malignant neoplasm to brain Symptomatic
Item
symptomatic brain metastases
boolean
C0220650 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
Tyrosine kinase inhibitor
Item
prior treatment with any tyrosine kinase inhibitor
boolean
C1268567 (UMLS CUI [1])